Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Commerce Minister Piyush Goyal drives investment reforms on Singapore visit
3/10/2025
Commerce ministry recommends anti-dumping duty on solar cells from China for 3 yrs
3/10/2025
Sebi confirms market ban on Synoptics Tech, promoters for IPO fund diversion
3/10/2025
Trump gives Hamas Sunday 6 pm deadline to sign peace deal, warns 'all hell' will break out
3/10/2025
Yes Bank Q2 update : Advances grow 6.5% YoY, deposits see 7% uptick
3/10/2025
Bajaj Housing Finance Q2 update : Disbursals rise 32% YoY to Rs 15,900 cr ; AUM up 24%
3/10/2025
